Get the Stockscreener App
2.82
2.55%
0.07
Sonoma Pharmaceuticals Inc stock is traded at $2.82, with a volume of 10,278.
It is up +2.55% in the last 24 hours and up +1.44% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$2.75
Open:
$2.77
24h Volume:
10,278
Relative Volume:
0.06
Market Cap:
$3.68M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-1.8553
EPS:
-1.52
Net Cash Flow:
$-5.20M
1W Performance:
-2.76%
1M Performance:
+1.44%
6M Performance:
-9.62%
1Y Performance:
-24.15%
1-Day Range:
$2.7413
$2.85
1-Week Range:
$2.68
$2.90
52-Week Range:
$2.318
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Certain Options of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Restricted Stock Units of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Warrants of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Preferred stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf - AccessWire
Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf - Marketscreener.com
Sonoma Pharmaceuticals (SNOA) Surges Amid Positive Analyst Ratin - GuruFocus.com
Unveiling the Future: Animal Wound Care Market to USD 1.24 BILLION IN 2023, Forecast by 2030, Featuring a C... - WhaTech
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada - AccessWire
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - AccessWire
Scar Treatment Market to See Booming Growth 2024-2031 | Bausch - openPR
Keloid Treatment Market Latest Report 2023-2031 - InsightAce Analytic
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Recent Developments in the Eye Skin Care Market - openPR
Keloid Treatment Market: Insights Predicting a $4.72 Billion Valuation by 2031 - WhaTech
Hypertrophic Scar Treatment Market Growth, Trends, and Industry Share Analysis (2024-2032) - News in Assen
Sonoma Pharmaceuticals (SNOA) Shares Surge Amid Positive Market Activity - GuruFocus.com
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Williams-Sonoma, Inc. (WSM) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
South Korea Topical scar treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Topical scar treatment Market Size & Outlook, 2030 - Grand View Research
Scar Treatment Market Top Industry Players РPerrigo Company, Smith & Nephew, Alliance Pharma, Rejûvaskin - Cauverynews
Sonoma Pharmaceuticals (SNOA) Stock Rises Amid Financial Report Insights - GuruFocus.com
Williams-Sonoma (WSM) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Scar Management Market Set to Grow at 5.61% CAGR, Projected to Reach $1.64 Billion by 2031 - WhaTech
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200-Day Moving Average of $0.56 - MarketBeat
Here's Why Williams-Sonoma (WSM) Gained But Lagged the Market Today - Yahoo Finance
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
SONO’s latest rating updates from top analysts. - Knox Daily
Top investors say Sonos Inc (SONO) ticks everything they need - SETE News
15,500 Shares in Sonoco Products (NYSE:SON) Acquired by Skandinaviska Enskilda Banken AB publ - Defense World
Federated Hermes Inc. Sells 466 Shares of Sonoco Products (NYSE:SON) - Defense World
Intubation Tubes Market Report Details Growth Drivers, Opportunities, Share Report And Forecast To 2033 - WhaTech
Hypertrophic And Keloid Scar Treatment Market Advancements Highlighted by Size, Growth,Outlook Report 2033 - WhaTech
Scar Treatment Global Market Report 2024: Growth Drivers and Dynamics 2033 - WhaTech
Sei Investments Co. Has $75.60 Million Position in Sonoco Products (NYSE:SON) - Defense World
Ameritas Investment Partners Inc. Reduces Stock Position in Sonoco Products (NYSE:SON) - Defense World
Sonoma Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - MSN
AE Wealth Management LLC Buys 12,401 Shares of Sonoco Products (NYSE:SON) - Defense World
Richardson Financial Services Inc. Sells 1,295 Shares of Sonoco Products (NYSE:SON) - Defense World
China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma Pharmaceuticals Inc. (SNOA)’s Day in Review: Closing at 3.83, Down by -10.93 - The Dwinnex
Financial Fitness Check: Examining Sonos Inc (SONO)’s Key Ratios - The Dwinnex
Keloid Treatment Market Poised for Growth, Expected to Reach USD 5.6 Billion by 2033 at a 3.8% of CAGR - Market Research Blog
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Pass Above 200-Day Moving Average of $0.33 - MarketBeat
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above Two Hundred Day Moving Average of $0.33 - Defense World
Sonoma Pharmaceuticals regains Nasdaq compliance - Investing.com
MQS Management LLC Purchases 7,448 Shares of Sonoco Products (NYSE:SON) - Defense World
Sonoma Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule - StockTitan
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):